Cannabis Abstinence and Neurocognitive Assessment in Adolescence

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15-18
SponsorUniversity Hospital Pilsen

About this trial

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

Eligibility criteria

Qualifiers

Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

Disqualifiers

psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.

somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.

Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.

Trial design

Treatments tested in this trial

  • Neurocognitive assessment
  • Urine toxicological assessment

Treatment groups

29 Participants
are divided into 1 treatment group

Sponsors and collaborators